Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Newleos Therapeutics receives $15.5M grant from NIDA/NIH to advance NTX-2001 for cocaine and alcohol use disorders through clinical trials.
Nov 04, 2026
BostonBiotechnologyHealth CareTherapeutics
Description
Newleos Therapeutics, a Boston-based clinical-stage biotech company, received a $15.5M grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The funding will support development of NTX-2001 in cocaine use disorder through Phase 1 drug-drug interaction and Phase 2 efficacy studies. The company is also conducting Phase 1b studies for alcohol use disorder and holds FDA Fast Track designation for NTX-2001 in AUD. Newleos focuses on neuropsychiatric mechanisms targeting multiple ion channels to reduce side effects and improve treatment outcomes.
Company Information
Company
Newleos Therapeutics
Location
Boston, Massachusetts, United States
About
Newleos Therapeutics is a clinical-stage biotechnology company based in Boston, MA, developing new treatments for neuropsychiatric disorders. The company focuses on neuropsychiatric mechanisms of action to reduce side effects and improve outcomes compared to current standard of care. Their platform includes clinical-stage, oral small molecules targeting GABAA-γ1, V1a, TAAR1, and GABAA-α5 for treatment of general anxiety, social anxiety, substance use disorders, and cognitive impairment. They are advancing NTX-2001 in cocaine use disorder and alcohol use disorder with FDA Fast Track designation.
Predictive Intelligence
Strategic
ML-powered predictions for Newleos Therapeutics's next move
BostonBiotechnologyHealth CareTherapeutics